Related Experiment Video
Updated: Aug 10, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Inhibitory effects of SEL201 in acute myeloid leukemia
Ewa M Kosciuczuk1,2,3, Aroop K Kar1,4, Gavin T Blyth1,2
1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Abstract:
MAPK interacting kinase (MNK), a downstream effector of mitogen-activated protein kinase (MAPK) pathways, activates eukaryotic translation initiation factor 4E (eIF4E) and plays a key role in the mRNA translation of mitogenic and antiapoptotic genes in acute myeloid leukemia (AML) cells. We examined the antileukemic properties of a novel MNK inhibitor, SEL201. Our studies provide evidence that SEL201 suppresses eIF4E phosphorylation on Ser209 in AML cell lines and in primary patient-derived AML cells. Such effects lead to growth inhibitory effects and leukemic cell apoptosis, as well as suppression of leukemic progenitor colony formation. Combination of SEL201 with 5'-azacytidine or rapamycin results in synergistic inhibition of AML cell growth. Collectively, these results suggest that SEL201 has significant antileukemic activity and further underscore the relevance of the MNK pathway in leukemogenesis.
Insights
A novel MAPK interacting kinase (MNK) inhibitor, SEL201, effectively targets acute myeloid leukemia (AML) cells by inhibiting eIF4E phosphorylation. SEL201 demonstrates significant antileukemic properties and synergistic effects when combined with other therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Mitogen-activated protein kinase (MAPK) interacting kinase (MNK) pathway is crucial for mRNA translation of key genes in acute myeloid leukemia (AML).
- Activation of eukaryotic translation initiation factor 4E (eIF4E) by MNK promotes leukemic cell survival and proliferation.
Purpose of the Study:
- To evaluate the antileukemic potential of SEL201, a novel MNK inhibitor.
- To investigate the effects of SEL201 on eIF4E phosphorylation and downstream signaling in AML.
Main Methods:
- Treatment of AML cell lines and primary patient-derived AML cells with SEL201.
- Assessment of eIF4E phosphorylation at Ser209.
- Evaluation of cell growth inhibition, apoptosis induction, and progenitor colony formation.
- Combination studies with 5'-azacytidine and rapamycin.
Main Results:
- SEL201 effectively suppressed eIF4E phosphorylation on Ser209 in AML cells.
- SEL201 induced significant growth inhibition and apoptosis in leukemic cells.
- SEL201 inhibited leukemic progenitor colony formation.
- Combination therapy with SEL201 demonstrated synergistic inhibition of AML cell growth.
Conclusions:
- SEL201 exhibits potent antileukemic activity against AML.
- Targeting the MNK pathway with SEL201 is a promising therapeutic strategy for AML.
- SEL201 shows synergistic effects with standard AML therapies, warranting further clinical investigation.
